Scientific evidence indicates that the risk of acquiring a severe pneumococcal infection is higher in people over the age of 60, and in adult populations with certain risk conditions, such as people with chronic procedures or diseases that impair ability, in addition to early age. Weakened detection of disease resistance.
For this reason, the Ministry of Health and the Cantabrian Health Service (SCS) will offer the 20-valent conjugate pneumococcal vaccine to the adult population aged 60 or over, as well as to those at risk.
Cantabria thus introduces a 20-valent conjugate vaccine (VCN20) against pneumococcal infection (‘Streptococcus pneumoniae’), which replaces the 23-valent polysaccharide pneumococcal vaccine currently used in the adult population. This new vaccine provides stronger protection as well as longer immune memory.
People aged 60 or over who have not yet been vaccinated against pneumococcus, as well as people between 18 and 59 who have a condition or present with moderate or high risk factors, to receive a single-dose You can take an appointment with your health center by May 22. Diet.
Comprehensive protection in a single dose
Infection by ‘Streptococcus pneumoniae’ produces a wide range of pathologies such as pneumonia, otitis media, mastoiditis, sinusitis and other common diseases of the upper respiratory tract. In addition, it can lead to more serious complications ranging from invasive pneumococcal disease (IPD), such as bacteremic pneumonia, meningitis or sepsis, which although less frequent, lead to greater morbidity and mortality.
The vaccine Cantabria will immunize includes protection against 20 serotypes of pneumococcus, which is responsible for 70 percent of hospitalized pneumococcal pneumonia cases in adults.
For these purposes, the vaccine is indicated in people with chronic cardiovascular disease, except for arterial hypertension; chronic respiratory disease, including cystic fibrosis and asthma, that do not require immunosuppressive treatment; chronic neurological disease with difficulties in the management of secretions; chronic and celiac liver disease; diabetes mellitus; Liquor; smokers, even if it is a daily cigarette; people with severe COVID-19 with hospitalization; People institutionalized in nursing homes, regardless of age, and people with a history of invasive pneumococcal disease.
Risk group
There are also plans for vaccination of adults regardless of age with solid organ transplantation (TOS) or hematopoietic progenitors (HSCT); with congenital or acquired immunodeficiencies: humoral (except selective IgA deficiency), cellular or combined, complement deficiencies and phagocytosis disorders; any malignancy, hematologic, or solid organ; HIV infection; National Kidney Foundation Stage 4 and 5 Chronic Renal Failure and Nephrotic Syndrome; People with chronic diseases susceptible to receiving immunosuppressive treatment, including those with steroids at immunosuppressive doses or with biological agents, such as inflammatory bowel disease, rheumatic disease, severe asthma, paroxysmal nocturnal hemoglobinuria, hemolytic uremic syndrome, myasthenia gravis, etc.
People with physical or functional asplenia (splenic dysfunction), including sickle cell disease and other severe hemoglobinopathies, are also considered at risk, and therefore more susceptible to vaccination; are being treated with eculizumab (Soliris), or long-acting derivatives; down’s syndrome; cerebrospinal fluid fistula; As well as carriers of a cochlear transplant or likely to receive it.
